BUZZ-Leerink Partners lowers PT on drugmaker Regeneron
Leerink Partners lowers PT on drugmaker Regeneron Pharmaceuticals REGN.O to $762 from $880; maintains rating of "market perform"
Brokerage says it lowered 2025 EPS estimates to $40.96 from $44.01 due to REGN's eye drug Eylea franchise pressures and investment spending requirements; analysts on average estimate 2025 EPS to be $44.76, according to data compiled by LSEG
Leerink notes REGN may face potential pricing pressure on Eylea HD in international markets outside of U.S.
Last year, REGN reported Q3 sales of $392 mln for higher dose version of Eylea, missing expectations of $417 mln
Brokerage says it expects REGN to defend its Eylea 2mg market share against Amgen's AMGN.O biosimilar, Pavblu
Expects U.S. Eylea sales to be constrained due to lack of pre-filled syringe, monthly dosing and RVO indication
REGN fell 21.3% in 2024
Related Articles
National Debt Bomb Ignited? Musk Warns U.S. Will Be 1000% Bankrupt Without AI
TradingKey - Tesla (TSLA) CEO Elon Musk recently issued another warning regarding the rapidly ballooning U.S. national debt. He stated clearly that without artificial intelligence and robotics, the United States will inevitably head toward fiscal bankruptcy.
Tesla Stock Outlook: Competing With Rivian, Robotaxi Potential, and 2026 Prospects
There is much conversation about the prospect of investing in Tesla (TSLA) as we move closer to 2026. The volatility of its share price in 2025 is leading many investors to consider if they should purchase shares of Tesla given the alternatives available in terms of electric vehicles (Rivian, etc.).
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 market
